Nightingale Health logo
  • Livit app
  • Healthy Years
  • Lifelong health
Download
en
  • fi

For investors

  • Nightingale as an investment
  • Financial information
  • Share and shareholders
  • Governance
  • Investor relations
  • Releases
  • Reports and recordings
  • Key strengths
  • CEO's greetings
  • Operational environment
  • Strategy
  • Dividends policy
  • Key figures
  • Share information
  • Share monitor
  • Shareholders
  • Authorisations
  • Forecasts and analysis reports
  • IPO 2021
  • Governance principles
  • General Meeting
  • Extraordinary General Meeting 2023
  • Annual General Meeting 2022
  • Board of Directors
  • Management Team
  • Remuneration
  • Risk management
  • Insider management
  • Auditor
  • Certified Adviser
  • Articles of Association
  • Code of Conduct
  • Investor calendar
  • Contacts
  • Disclosure policy
  • Company releases
  • Press releases
  • Managers' transactions
  • Reports
  • An hour with Nightingale recordings
Nightingale as an investment ↘
  • Key strengths
  • CEO's greetings
  • Operational environment
  • Strategy
  • Dividends policy
Financial information ↘
  • Key figures
Share and shareholders ↘
  • Share information
  • Share monitor
  • Shareholders
  • Authorisations
  • Forecasts and analysis reports
  • IPO 2021
Governance ↘
  • Governance principles
  • General Meeting
  • Extraordinary General Meeting 2023
  • Annual General Meeting 2022
  • Board of Directors
  • Management Team
  • Remuneration
  • Risk management
  • Insider management
  • Auditor
  • Certified Adviser
  • Articles of Association
  • Code of Conduct
Investor relations ↘
  • Investor calendar
  • Contacts
  • Disclosure policy
Releases ↘
  • Company releases
  • Press releases
  • Managers' transactions
Reports and recordings ↘
  • Reports
  • An hour with Nightingale recordings

Press releases

  • Nightingale Health to publish half-year report for July – December 2022 on 23 March 2023 – Mar 15, 2023
  • Strategic collaboration in Estonia progresses: Nightingale Health completes the analysis of 200,000 Estonian Biobank samples – Mar 08, 2023
  • Nightingale Health combines genetics with its unique blood test results in Livit by Nightingale Health service – Feb 03, 2023
  • Nightingale Health to open laboratory in the United Kingdom in 2023 – Jan 25, 2023
  • Independent study: Nightingale Health’s blood test shown to enhance health check-ups by predicting many diseases at once – Oct 07, 2022
  • Nightingale Health to publish Financial Statements Release for financial year July 2021–June 2022 on 29 September 2022 – Sep 23, 2022
  • Further landmark evidence released to showcase the ability of Nightingale Health’s technology to predict hundreds of diseases from a single blood sample – Jun 14, 2022
  • Nightingale Health partners with Physitrack, expanding the availability of its preventative wellbeing service Livit to Germany, the UK and in the Nordics – Jun 08, 2022
  • Analysis: Nightingale Health’s net impact among the top 7 percent of companies worldwide – May 31, 2022
  • Nightingale Health launches consumer service Livit by Nightingale Health utilizing its at-home testing solution – Mar 31, 2022
  • Nightingale to publish half-year report for July – December 2021 on 24 February 2022 – Feb 16, 2022
  • Nightingale’s information security management certification continued with outstanding results in surveillance audit – Jan 20, 2022
  • Nightingale Home service launched with major Finnish pharmacy chain Yliopiston Apteekki – Dec 22, 2021
  • Nightingale’s preventative health service launched at Shin-Oyama City Hospital in Japan – Dec 21, 2021
  • Nightingale expands its Japan laboratory – Dec 17, 2021
  • Nightingale’s corporate health service piloted at Mitsui headquarters in Tokyo – Nov 18, 2021
  • Nightingale launches Nightingale Home and Nightingale Pro service models – Nov 15, 2021
  • Recording of event: An hour with Nightingale – Oct 28, 2021
  • Nightingale and BioBank Japan to realise personalised medicine and preventative health in Japan – Oct 28, 2021
  • Invitation to event: An hour with Nightingale – Oct 18, 2021
  • Fimea inspected Nightingale’s regulatory compliance with the requirements for manufacturer of medical device – Oct 14, 2021
  • Nightingale receives CE marking for its at-home blood collection kit – Oct 07, 2021
  • Nightingale to publish Financial Statements Release for financial year July 2020–June 2021 on 15 September 2021 – Sep 07, 2021
  • Reaktor becomes strategic partner of Nightingale to accelerate international growth – May 04, 2021
  • Nightingale intends to launch an initial public offering and listing on Nasdaq First North Growth Market Finland – Feb 19, 2021
  • Nightingale Health Accelerates the Availability of Its At-Home Blood Testing Solution by Launching an Early-Access Pilot for 10,000 Consumers in Finland – Feb 17, 2021
  • Nightingale Health and Estonian Biobank Agree Strategic Collaboration Aiming to Work Towards Estonian Biobank’s Nationwide Early Disease Prevention in Estonia – Feb 04, 2021
  • Nightingale to roll-out novel preventative solution for COVID-19 enabling safe returns to work post lockdowns – Jul 06, 2020
  • Nightingale Health’s blood analysis shows great promise for preventative COVID-19 and Pneumonia Risk Detection – Jun 15, 2020
  • Nightingale Health Opens EUR 50-80M Private Placement Round with Carnegie as its Advisor to Bring Nightingale’s Preventative Health Technology to International Markets – Nov 21, 2019
  • Nightingale Health Announces Strategic Partnership with Kirin and Mitsui to Bring Nightingale’s Internationally Recognised Blood-Testing Services to the Japanese Market – Nov 15, 2019
  • New technology links chronic inflammation with increased risk of a wide range of diseases and shorter lifespan – Nov 15, 2018
  • Healthcare start up Nightingale invited to solve world’s biggest health problem with the UN and MIT – Feb 17, 2017
  • Pioneering Healthcare Company changes name from Brainshake to “Nightingale Health” – Feb 17, 2017
  • Blood Analysis Company Brainshake Closes Funding of €2M Three Months after First Round – Oct 03, 2016
  • Brainshake Closes €3.5M to Advance Regulatory Approval of Blood Analysis Service – Sep 14, 2016

Nightingale Health

  • About us
  • Contact
  • Careers
  • News
  • Investors

Livit

  • Livit app
  • Healthy Years
  • Lifelong health
  • FAQ
  • Blog
  • Download

Our solutions

  • For health industry
  • For researchers
  • For employers
  • For wellness professionals
  • Nightingale Health Japan
  • My Nightingale – Sign in

Read more

  • Technology
  • Publications

Nightingale Health Plc

Mannerheimintie 164a,
00300 Helsinki,
Finland

© 2023 Nightingale Health

Terms & policies

  • Livit app
  • Healthy Years
  • Lifelong health
Download
  • en
  • fi